Vivos Therapeutics, Inc.
VVOS- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001716166
No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Vivos Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 27 | 30 | +3 |
| Shares | 1.57M | 5.01M | +3.45M (+220.1%) |
| Value | $629.7K | $1.71M | +$1.08M (+171.7%) |
New holders (8)
Institutions that held Vivos Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Strategic Wealth Designers | 3,219,705 | $1.10M | 0.20% |
| Godsey & Gibb Associates | 92,999 | $31.7K | 0.00% |
| Two Sigma Investments, LP | 91,013 | $31.0K | 0.00% |
| Virtu Financial LLC | 46,013 | $16.0K | 0.00% |
| Millennium Management LLC | 19,118 | $7.00K | 0.00% |
| Cutler Group LP | 6,100 | $2.00K | 0.00% |
| FMR LLC | 3,600 | $1.23K | 0.00% |
| Simplex Trading, LLC | 548 | $0 | 0.00% |
Sold out (5)
Institutions that held Vivos Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Citadel Advisors LLC | 35,209 | $14.2K |
| UBS Group AG | 18,812 | $7.53K |
| Two Sigma Securities, LLC | 12,213 | $4.91K |
| Rockefeller Capital Management L.P. | 3,500 | $1.00K |
| Bank of America Corp | 46 | $18 |